Trial
NCT04126031
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
Allergan
Condition
Gram-negative Bacterial Infection
Intervention
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3
Why stopped
Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-26